Amiodarone HCl
Ion channel antagonist; Autophagy modulator. Suppresses SARS-CoV infection in cells through inhibition of late endosomes. Yang and Shen Int J Biol Sci., 16:1724–1731, Mar 15 2020, https://dx.doi.org/10.7150%2Fijbs.45498; Si et al. bioRxiv, Apr 14 2020, https://doi.org/10.1101/2020.04.13.039917.
- Datasheet: view or download
- Applications:Approved drug (U.S.); in COVID-19 clinical trials
Biochemicals & reagents
19774-82-4
1) Yamase et al. (2012), Effectiveness of amiodarone verus bepridil in achieving conversion to sinus rhythm in patients with persistent atrial fibrillation: a randomized trial; Heart, 98 1067 2) Di Matola et al. (2000), Amiodrarone induces cytochrome c release and apoptosis through an iodine-independent mechanism; J. Clin. Endocrinol. Metab., 85 4323 3) Capell et al. (2011), Rescue of progranulin deficiency associated with frontotemporal lobar degeneration by alkalizing reagents and inhibition of vacuolar ATPase; J. Neurosci., 31 1885 4) Lan et al. (2014), Autophagy-preferential degradation of MIR224 participates in hepatocellular carcinoma tumorigenesis; Autophagy, 10 1687
681.77
Room Temperature
Amiodarone is a nonselective ion channel blocker used as Class III antiarrhythmics (1). This compound induces cytochrome c release and induces apoptosis (2), is an alkalizing agent which stimulates progranulin (GRN) production and prevents GRN-dependent neurodegeneration (3). It also induces autophagy and suppresses hepatocellular carcinoma tumorigenesis via autophagy-mediated MIR224 degradation in vitro and in vivo (4).